Kenvue Inc. (NYSE:KVUE) Shares Sold by Cohen Klingenstein LLC

Cohen Klingenstein LLC lessened its stake in shares of Kenvue Inc. (NYSE:KVUE) by 4.9% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 28,964 shares of the company’s stock after selling 1,485 shares during the period. Cohen Klingenstein LLC’s holdings in Kenvue were worth $618,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Leo Wealth LLC grew its position in shares of Kenvue by 0.3% in the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after purchasing an additional 481 shares during the period. Alerus Financial NA lifted its holdings in shares of Kenvue by 0.3% during the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after acquiring an additional 491 shares during the period. Massmutual Trust Co. FSB ADV boosted its position in shares of Kenvue by 6.2% in the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after acquiring an additional 492 shares during the last quarter. Wolff Wiese Magana LLC increased its position in Kenvue by 0.7% during the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after purchasing an additional 501 shares during the last quarter. Finally, Marathon Capital Management raised its stake in Kenvue by 0.3% during the second quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after purchasing an additional 514 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Bank of America upped their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Barclays reduced their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday. UBS Group lowered their price target on Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Trading Down 0.4 %

Shares of NYSE KVUE opened at $21.11 on Friday. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The business has a fifty day simple moving average of $22.42 and a 200-day simple moving average of $21.66. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company has a market cap of $40.46 billion, a price-to-earnings ratio of 38.37, a P/E/G ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same period last year, the company posted $0.31 EPS. The business’s quarterly revenue was down .4% compared to the same quarter last year. Sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.89%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.